Literature DB >> 30504400

Expression of Metallothionein I/II and Ki-67 Antigen in Graves' Disease.

Pawel Domoslawski1, Bartosz Pula2, Mateusz Olbromski2, Beata Wojtczak3, Tadeusz Lukienczuk3, Marzenna Podhorska-Okolow2, Piotr Dziegiel2,4.   

Abstract

BACKGROUND/AIM: The expression of metallothionein I/II (MT-I/II) was examined in thyroids of Graves' disease (GD) and nodular goiter (NG) patients to determine its role as a potential marker of proliferation and autoimmune inflammation in the thyroid. PATIENTS AND METHODS: MT-I/II and Ki-67 antigen expression was studied using immunohistochemistry in 72 GD and 24 NG patients.
RESULTS: MT-I/II expression was noted in the cytoplasm and nuclei of thyrocytes of GD and NG patients. Cytoplasmic and nuclear MT-I/II expression correlated strongly with GD (r=0.51; p<0.0001) and NG (r=0.50; p=0.0137). Cytoplasmic MT-I/II expression was significantly higher in GD (mean IRS 9.24±2.36) than in NG (mean IRS 7.13±2.51; p=0.0006) and correlated positively with Ki-67 antigen expression (r=0.28; p=0.0165). Nuclear MT-I/II expression was elevated in GD (mean 3.53±0.65) in comparison to NG (mean 2.96±0.86; p=0.028).
CONCLUSION: MT-I/II may be a potential marker of GD in the thyroid and may be potentially involved in thyrocytes' proliferation. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Graves' disease; Ki-67; Metallothionein; nodular goiter; thyroid

Mesh:

Substances:

Year:  2018        PMID: 30504400     DOI: 10.21873/anticanres.13059

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Comparison of TMA Technique and Routine Whole Slide Analysis in Evaluation of Proliferative Markers Expression in Laryngeal Squamous Cell Cancer.

Authors:  Urszula Ciesielska; Aleksandra Piotrowska; Christopher Kobierzycki; Wojciech Pastuszewski; Marzenna Podhorska-Okolow; Piotr Dziegiel; Katarzyna Nowinska
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.